Tesamorelin
Also known as: Egrifta, TH9507
A synthetic GHRH analog FDA-approved for reducing excess abdominal fat in HIV-associated lipodystrophy. Also studied for cognitive benefits and NAFLD.
Mechanism of Action
Stimulates pituitary GH release in a physiological pulsatile pattern. The trans-3-hexenoic acid modification improves receptor binding and stability.
Dosing Protocol
2mg subcutaneous daily, typically injected in the abdomen.
Open peptide calculatorReconstitution
2mg vial + 2mL sterile water (provided with kit).
Storage
Lyophilized: room temperature. Reconstituted: use immediately or refrigerate.
Side Effects
- ●Injection site reactions
- ●Joint pain
- ●Peripheral edema
- ●Paresthesia
Key Research Findings
- ●FDA-approved: reduced visceral adipose tissue by 15% in HIV patients
- ●Improved cognitive function in older adults (GROW study)
- ●Reduced liver fat in NAFLD pilot studies
Latest Verified Lab Report
No lab reports available for Tesamorelin yet.
Community-funded testing results will appear here.
Vendor Trust Leaderboard
Trust leaderboard coming soon.
Vendor rankings based on verified lab test results.
Active Deals
15% off with code at checkout.
10% off with code at checkout.
10% off — discount applied automatically via referral link.
10% off with code at checkout.
Sponsored Ad Space
Advertise with usResearch Use Only
This information is provided for educational and research purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional before using any research compounds.